Elanco Animal Health, commonly referred to as Elanco, is a global pharmaceutical and biotechnology corporation dedicated exclusively to animal health. The company develops, manufactures, and markets a wide range of medicines, vaccines, parasiticides, nutritional products, and health solutions for both companion animals and farm animals. As of 2026, Elanco positions itself as one of the world’s largest independent animal-health companies, with products available in more than 90 countries and a portfolio covering species such as dogs, cats, cattle, poultry, swine, and sheep.[1]

The corporate purpose of Elanco is “making life better for animals makes life better,” while its longstanding vision remains “Food and Companionship Enriching Life.”[1] Its principal executive offices are located at 450 Elanco Circle, Indianapolis, Indiana 46221.[2]

Key Facts

Elanco functions essentially as the animal-health counterpart to major human pharmaceutical companies. Rather than focusing on human medicine, it concentrates on preventing and treating diseases in animals to improve health and productivity. Its operations are broadly divided into two primary segments:

• Pet Health: Products for dogs and cats, including parasiticides, vaccines, dermatology treatments, and therapeutics.
• Farm Animal Health: Products and technologies for livestock and poultry, including cattle, poultry, swine, and sheep.

The company serves a diverse customer base that includes veterinarians, pet owners, farmers, livestock producers, animal-health professionals, retailers, distributors, and food-production businesses. In its 2025 annual filing, Elanco described its focus as providing products and services that prevent and treat disease in both farm animals and pets across its global market.[1]

Etymology and Early Roots

The name Elanco is derived from “Eli Lilly and Company.” The brand emerged in 1960 following the reorganization of Eli Lilly’s agricultural and animal-science activities.[2] While the modern business was formally established in the mid-20th century, Eli Lilly’s involvement in veterinary medicine dates back to 1892, including early work on rabies-related products.

In 1953, Eli Lilly introduced an antibiotic specifically for veterinary use. The following year, in 1954, the company formally organized its plant and animal-science activities into an Agricultural and Industrial Sales Division, an event generally regarded as the foundation of modern Elanco.[1] A notable origin story from this era involves Lilly executives who, upon learning during a flight that an existing human medicine might have applications in cattle, immediately contacted Iowa State University to pursue the opportunity, contributing significantly to the firm’s agricultural foundation.

Transition from Agriculture to Animal Health

Historically, Elanco was involved in both agricultural products and animal health. Significant early products included Treflan, a soybean herbicide that became Lilly’s top-selling product for over a decade, and Rumensin, introduced in 1975 to improve feed efficiency and control coccidiosis in cattle. Over subsequent decades, the company shifted its focus away from crop products toward animal health. By the early 2000s, it had evolved into a major farm-animal-health business.

Expansion into the companion animal sector accelerated in 2007 with the acquisition of Ivy Animal Health, which brought products like Reconcile for canine separation anxiety. This acquisition marked a strategic pivot toward becoming a broader animal-health company serving both pets and livestock. Throughout the 2010s, Elanco continued to expand through acquisitions and asset deals involving companies such as Janssen and Pfizer.

Independence and Bayer Acquisition

A pivotal moment in Elanco’s history was its separation from Eli Lilly and Company. On September 18, 2018, Elanco began trading independently on the New York Stock Exchange under the ticker ELAN, with the separation process completing in 2019.[1] This transition transformed Elanco from a division within Lilly into an independent, pure-play global animal-health company.

In August 2020, Elanco completed the acquisition of Bayer Animal Health for approximately $6.89 billion. This transaction dramatically increased the company’s scale, adding major pet-health brands, parasiticide products, international operations, direct-to-consumer expertise, and manufacturing infrastructure. Following the combination, Elanco stated that pet health would represent approximately 50% of its revenue, effectively transforming it into a global competitor with one of the industry’s most extensive portfolios.

Following its expansion, Elanco manages a portfolio comprising more than 200 brands.[3]

Pet Health

This segment includes products frequently encountered by pet owners, particularly in flea, tick, and parasite control. Key brands include:

• Credelio
• Credelio CAT
• Credelio Quattro
• Seresto
• Advantage
• Advantage II
• Advantage Multi
• K9 Advantix II
• Trifexis
• Comfortis
• Interceptor Plus[3]

These products address infestations and infections caused by fleas, ticks, heartworm, roundworms, hookworms, tapeworms, and other parasites.[3] Beyond parasiticides, Elanco develops therapeutic medicines for specific medical conditions in companion animals, including dermatology, pain and mobility, osteoarthritis, gastrointestinal issues, behavioral conditions, cardiovascular/metabolic disorders, and infectious diseases.

A significant recent addition to the portfolio is Zenrelia, an allergy and dermatology medicine for dogs. By 2026, Elanco described Zenrelia as having reached “blockbuster” status based on trailing four-quarter revenue, identifying it as a primary driver of company growth.[1] This underscores a strategic shift toward higher-value therapeutic products alongside established parasite-control brands.

Farm Animal Health

The Farm Animal Health segment supports cattle, poultry, swine, and sheep with products addressing disease prevention, parasite control, vaccination, feed efficiency, nutrition, productivity, food safety, and animal welfare. Elanco positions animal health as integral to the broader food system, arguing that healthier livestock leads to lower disease losses, improved productivity, enhanced food safety, and more efficient production.

Research and development (R&D) are central to Elanco’s business model. The company invests in discovering new veterinary drugs, vaccines, biological medicines, parasiticides, delivery technologies, diagnostics, and sustainability-related agricultural solutions. Elanco operates 17 dedicated R&D and manufacturing sites globally.

Biologics, particularly monoclonal antibodies, have become an increasingly important focus. In August 2026, Elanco completed a 25,000-square-foot expansion of its Elwood, Kansas manufacturing facility to increase monoclonal-antibody capacity. At that time, the company identified itself as one of only two animal-health firms with monoclonal-antibody solutions on the market.[1]

In June 2026, Elanco announced Elanco Ventures, a corporate venture-capital platform backed by a $25 million multi-year commitment. This initiative targets emerging technologies in animal therapeutics, animal-health technology, One Health, and biotechnology, providing an external avenue for innovation alongside internal R&D.[1]

Elanco’s strategy is encapsulated in its Innovation, Portfolio, Productivity (IPP) framework, which focuses on four pillars:

1. Innovation: Developing new products with significant clinical or economic value.
2. Portfolio Productivity: Concentrating resources on high-return products and markets.
3. Pet-Health Growth: Expanding therapeutic and preventive portfolios for dogs and cats.
4. Farm-Animal Productivity: Creating technologies for efficient, safe, and sustainable protein production.[1]

Sustainability is increasingly linked to animal health in Elanco’s corporate narrative. The company posits that better animal health reduces losses and improves production efficiency, potentially lowering resource use per unit of food. Leadership has emphasized developing products that positively impact climate-related challenges in livestock production.

This aligns with the concept of One Health, which views animal, human, and environmental health as interconnected. Elanco argues that healthy livestock contributes to greater food-production efficiency, reduced disease losses, safer protein, and better resource utilization, framing its role as safeguarding the food system and maintaining access to affordable animal protein.[1]

Elanco is a publicly traded pharmaceutical company with shares listed on the New York Stock Exchange under the symbol ELAN. Around the time of its new headquarters announcement, the company reported approximately $4.7 billion in annual revenue. For 2026, initial projections estimated full-year revenue between $4.95 billion and $5.02 billion, though this outlook was subsequently updated during the year.[1]

As of September 2026, Jeffrey N. Simmons serves as President and Chief Executive Officer.[1] Simmons has led the company through its separation from Eli Lilly, its NYSE listing, the Bayer Animal Health integration, and its subsequent innovation-focused strategy. Elanco notes he possesses approximately 30 years of industry experience and has spent about 15 years leading the organization. The board of directors is chaired by Lawrence E. Kurzius.[4]

Elanco maintains a significant international footprint, with products sold in more than 90 countries.[1] Its operations span veterinary channels, agricultural channels, distributors, retailers, and other commercial partners, adapting to local variations in parasite pressures, regulations, and consumer spending.

In October 2025, Elanco opened a new global headquarters in Indianapolis, Indiana. Designed as both a corporate office and innovation center, the campus connects to the city’s planned OneHealth Innovation District. It houses over 725 employees and facilitates collaboration among corporate, scientific, academic, and community organizations.[1]

In 2025, the company also announced plans to invest an additional $400 million in U.S. operations, R&D, manufacturing, and communities over five years.[1]

Elanco operates in a specialized sector alongside major competitors such as Zoetis, Boehringer Ingelheim, Merck Animal Health, Ceva Santé Animale, and Virbac. Unlike human pharmaceuticals, the animal-health market requires serving both professional veterinary channels and consumer pet-care markets. The acquisition of Bayer Animal Health was partly driven by the need to achieve sufficient scale to compete effectively across these diverse segments.

• 1892: Eli Lilly begins early involvement in veterinary medicine.
• 1953: Lilly introduces an antibiotic specifically for veterinary use.
• 1954: Agricultural and animal-science activities are formally organized, establishing modern Elanco.
• 1960: The Elanco brand is created.
• 1975: Rumensin becomes a key livestock-health product.
• 1990s: Focus shifts from plant products toward animal health.
• 2007: Acquisition of Ivy Animal Health strengthens pet-health business.
• 2010s: Major expansion through acquisitions and product deals.
• 2018: Elanco begins trading independently on the NYSE.
• 2019: Separation from Eli Lilly is completed.
• 2020: Completion of the $6.89 billion Bayer Animal Health acquisition.
• 2025: New global headquarters opens in Indianapolis.
• 2026: Expansion of biologics manufacturing, launch of Elanco Ventures, and continued emphasis on innovation-led growth.[1]

1. Form 10-K for Elanco Animal Health INC filed 02/24/2026
2. Contact Us
3. Pet Health Care Products | Your Pet & You
4. Board of Directors